



## ASX RELEASE

### Volpara confirms changes to Board of Directors

Wellington, NZ, 31 January 2020: [Volpara Health Technologies](#) ("Volpara" or "the Company"; ASX: VHT), a SaaS medical technology company whose AI imaging algorithms assist the early detection of breast cancer, is pleased to confirm the changes to the Board, as foreshadowed on 15 January, which contribute towards best-practice governance standards and enhance our expertise around patient data and US healthcare networks.

Today the following Board changes became effective:

- **Karin Lindgren**, a healthcare technology lawyer and senior IT executive, based in Boulder, Colorado, has joined the Board as an independent, non-executive Director. Karin has a STEM degree and brings in-depth knowledge of data privacy, US healthcare and has extensive personal networks across the IT landscape. In addition Karin has been granted 450,000 share options, in accordance with our standard policy for Board members, subject to shareholder approval at the AGM in August 2020.
- **Professor Sir Mike Brady**, has retired after 10 years of service on the Board.

Paul Reid, Chairman of Volpara, said "We welcome Karin and look forward to her contribution to the board, particularly in the area of healthcare IT and patient data. We are also sad to see Mike leave the board and thank him for his valuable contribution to the board and company over the past 10 years".

**ENDS**

### Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Volpara Health Technologies Limited

### For further information, please contact:

Ralph Highnam, CEO  
Volpara Health Technologies  
[ralph.highnam@volparasolutions.com](mailto:ralph.highnam@volparasolutions.com)  
t: +64 21 149 0541

Trevor Chappell  
WE Communications  
[WE-AUVolpara@we-worldwide.com](mailto:WE-AUVolpara@we-worldwide.com)  
t: +61 3 9866 1215

### ABOUT VOLPARA HEALTH TECHNOLOGIES LIMITED (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical applications for screening clinics provide feedback on breast density, compression, dose and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement and patient-tracking.

VHT's technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in 2016, VHT has raised A\$95 million, including A\$55 million in June 2019. VHT is based in Wellington, New Zealand.

At the end of June 2019, VHT acquired MRS, a company based in Seattle, WA. MRS provides mammography reporting systems to over 1,600 breast clinics and hospitals, and to VHT a much stronger US presence, experienced local headquarters, and accelerated sales through cross-selling opportunities.

For more information, visit [www.volparasolutions.com](http://www.volparasolutions.com)